Nexalin Technology, Inc.
NXL Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2021βFY2025
What Nexalin Technology, Inc. does
No business description yet.
- Legal name
- Nexalin Technology, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 25, 2026
- Accession Β· CIK
- 0001829126-26-002673
0001527352
Revenue and margins
Nexalin Technology, Inc. had $0.3M of revenue in fiscal 2025, up 78.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β in fiscal 2025, β of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Nexalin Technology, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 77.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Nexalin Technology, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.7M | $7.0M | $2.9M | $3.5M | $3.7M |
| Interest coverage | β73.1x | β30.9x | β146.8x | β | β |
| Current ratio | 0.3x | 3.8x | 8.1x | 7.2x | 4.8x |
| Quick ratio | 0.3x | 3.7x | 7.7x | 6.9x | 4.7x |
| Total assets | $0.8M | $7.4M | $3.6M | $4.2M | $4.6M |
| Total liabilities | $2.4M | $2.0M | $0.4M | $0.5M | $0.9M |
| Shareholders' equity | β$1.7M | $5.5M | $3.2M | $3.7M | $3.7M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 3 / 8 | 3 / 8 | 4 / 8 |
| Accruals ratio | β663.6% | 12.7% | β14.7% | β93.3% | β73.7% |
| Altman Z'' | β374.17 | β25.63 | β66.35 | β65.32 | β68.21 |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0.1M | $1.3M | $0.1M | $0.2M | $0.3M |
| Net interest income | β | β | $0.0M | β$0.0M | β$0.0M |
| Gross profit | $0.1M | $1.0M | $0.1M | $0.1M | $0.2M |
| Research and development | $0.1M | $0.5M | $1.9M | $1.2M | $1.1M |
| Operating income | β$6.0M | β$1.8M | β$5.7M | β$7.8M | β$8.4M |
| Interest expense | $0.1M | $0.1M | $0.0M | β$0.0M | β$0.0M |
| Pretax income | β | β | β$4.6M | β$7.6M | β$8.2M |
| Net income | β$6.1M | β$1.7M | β$4.6M | β$7.6M | β$8.2M |
| Diluted EPS | β | β$0.30 | β$0.63 | β$0.83 | β$0.50 |
| Diluted shares | β | 0.01B | 0.01B | 0.01B | 0.02B |
| Cash flow | |||||
| Cash from operations | β$1.1M | β$2.2M | β$3.8M | β$3.9M | β$5.0M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | β | β |
| Stock-based compensation | $4.5M | $0.3M | $2.4M | $3.6M | $3.1M |
| Balance sheet | |||||
| Cash and short-term investments | $0.7M | $7.0M | $2.9M | $3.5M | $3.7M |
| Current assets | $0.8M | $7.4M | $3.4M | $4.0M | $4.3M |
| Current liabilities | $2.4M | $1.9M | $0.4M | $0.5M | $0.9M |
| Inventory | $0.0M | $0.2M | $0.2M | $0.2M | $0.1M |
| Property and equipment, net | $0.0M | $0.0M | β | β | β |
| Intangible assets | β | β | $0.1M | $0.3M | $0.3M |
| Total assets | $0.8M | $7.4M | $3.6M | $4.2M | $4.6M |
| Total liabilities | $2.4M | $2.0M | $0.4M | $0.5M | $0.9M |
| Shareholders' equity | β$1.7M | $5.5M | $3.2M | $3.7M | $3.7M |
| Margins | |||||
| Gross margin | 85.1% | 72.5% | 76.9% | 78.3% | 79.7% |
| Operating margin | β4,176.7% | β138.7% | β5,145.7% | β4,596.7% | β2,782.1% |
| EBITDA margin | β4,176.3% | β138.7% | β5,145.3% | β | β |
| Net margin | β4,217.9% | β128.5% | β4,199.4% | β4,509.3% | β2,726.2% |
| Net interest share of revenue | β | β | 35.0% | β1.9% | β2.7% |
| Returns | |||||
| Return on capital employed | 373.8% | β33.4% | β177.6% | β211.0% | β223.9% |
| Return on equity | β | β89.4% | β107.0% | β221.1% | β221.5% |
| Return on assets | β806.4% | β41.5% | β84.0% | β193.7% | β185.6% |
| Return on tangible equity | β | β31.0% | β149.9% | β222.7% | β241.0% |
| Growth | |||||
| Revenue growth | β | 817.0% | β91.6% | 52.4% | 78.8% |
| Share count change | β | β | 32.0% | 25.3% | 77.9% |
| Financial health | |||||
| Interest coverage | β73.1x | β30.9x | β146.8x | β | β |
| Current ratio | 0.3x | 3.8x | 8.1x | 7.2x | 4.8x |
| Quick ratio | 0.3x | 3.7x | 7.7x | 6.9x | 4.7x |
| Capital allocation | |||||
| Stock comp / revenue | 3,107.6% | 20.5% | 2,180.1% | 2,110.6% | 1,035.6% |
| Quality scores | |||||
| Piotroski F-score | β | 2.0 | 3.0 | 3.0 | 4.0 |
| Altman Z'' | β374.2 | β25.6 | β66.3 | β65.3 | β68.2 |
| Accruals ratio | β663.6% | 12.7% | β14.7% | β93.3% | β73.7% |
Source: SEC EDGAR XBRL filings (CIK 0001527352). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.